Targeting the PD-1/PD-L1 axis has already shown significant clinical efficacy, particularly in triple-negative breast cancer (TNBC), where treatment with immune checkpoint inhibitors such as pembrolizumab and atezolizumab has significantly prolonged survival [60,61]. The gene discussed is PDCD1; the disease is triple-negative breast carcinoma.